http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2540119-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcce39a20bef16c3f04497659caba40f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-40 |
| filingDate | 2010-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7b262a55ab0b80e44e186dd46a9c180 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8691e05c29c81c99b0cb2bc875bd6f5d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b68820d7de52a9902e5f0155133a624 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_931fb6fe0b20a31018d41cab1e00f583 |
| publicationDate | 2015-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2540119-T3 |
| titleOfInvention | Compounds as cannabinoid receptor ligands |
| abstract | A compound according to formula (I), or a pharmaceutically acceptable salt, solvate, salt of a solvate, or a combination thereof, ** Formula ** wherein R1 is aryl, monocyclic heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; wherein each ring is independently substituted with one Rx group and optionally further substituted with 1, 2, 3, or 4 Ry groups; Rx is -C (> = NORf) Ra, - (CR1aR1b) q1-A1, alkenyl, or alkynyl; wherein alkenyl and alkynyl are substituted with one or two to groups A2; each Ry is independently G1d, alkyl, alkenyl, alkynyl, halogen, haloalkyl,> = N-CN,> = NORf, NO2, -CN, oxo, -ORf, -OC (O) Rf, -OC (O) N ( Rf) 2, -S (O) 2Rc, -S (O) 2N (Rf) 2, -C (O) Rf, -C (O) ORf, -C (O) N (Rf) 2, - N ( Rf) 2, -N (Rf) C (O) Rf, -N (Rf) S (O) 2Re, -N (Rf) C (O) O (Re), -N (Rf) C (O) N (Rf) 2, - (CR1cR1d) q3-ORf, - (CR1cR1d) q3- OC (O) Rf, - (CR1cR1d) q3-OC (O) N (Rf) 2, - (CR1cR1d) q3-S (O ) 2Re, - (CR1cR1d) q3-S (O) 2N (Rf) 2, - (CR1cR1d) q3-C (O) Rf, - (CR1cR1d) q3-C (O) ORf, - (CR1cR1d) q3-C (O) N (Rf) 2, - (CR1cR1d) q3-N (Rf) 2, - (CR1cR1d) q3-N (Rf) C (O) Rf, - (CR1cR1d) q3- N (Rf) S (O ) 2Re, - (CR1cR1d) q3-N (Rf) C (O) O (Rc), - (CR1cR1d) q3-N (Rf) C (O) N (Rf) 2, or - (CR1cR1d) q3-CN ; A1 is -ORa, -OC (O) Ra, -OC (O) N (Rb) (Rc), -N (Rb) (Rk), -C (O) O (Ra), -C (O) Ra , -S (O) 2Rd, -S (O) Rd, -SRd, - C (O) N (Rb) (Rc), -C (S) N (Rb) (Rc), -S (O) 2N (Rb) (Rc), -C (> = NORf) Ra, -CN, -N (Rc) C (O) Ra, -N (Rc) C (O) ORd, - N (Rc) S (O) 2Rd, -N (Rc) C (O) N (Rb) (Rc), -N (Rc) S (O) 2N (Rb) (Rc), G1a or G1b; each occurrence of A 2 is independently -ORa, -OC (O) Ra, -OC (O) N (Rb) (Rc), -N (Rb) (Rk), -C (O) O (Ra), - C (O) Ra, -S (O) 2Rd, -S (O) Rd, -SRd, -C (O) N (Rb) (Rc), -C (S) N (Rb) (Rc), - S (O) 2N (Rb) (Rc), -C (> = NORf) Ra, -CN, - N (Rc) C (O) R3, -N (Rc) C (O) ORd, -N (Rc ) S (O) 2Rd, -N (Rc) C (O) N (Rb) (Rc), -N (Rc) S (O) 2N (Rb) (Rc), or G1c; G1a is a 4-, 5-, 6-, or 7-membered monocyclic heterocycle having zero double bonds and one or two heteroatoms in the ring, where each ring is substituted with 1, 2, or 3 substituents selected independently from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, -OH, alkoxy, -C (O) O (alkyl), and hydroxyalkyl; G1b is optionally substituted cycloalkyl or optionally substituted cycloalkenyl; G1c is cycloalkyl, cycloalkenyl, aryl, heterocycle, or heteroaryl; each ring represented by G1b and G1c is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from the group consisting of oxo, alkyl, alkenyl, alkynyl, halogen, haloalkyl,> = N-CN, - C (> = NORf) Ra,> = N-ORf, -CN, NO2, oxo, -ORa, -OC (O) Ra, -OC (O) N (Rb) (Rc), -S (O) Rd , - S (O) 2Rd, -S (O) 2N (Rb) (Rc), -C (O) Ra, -C (O) ORa, -C (O) N (Rb) (Rc), -N (Rb) (Rc), -N (Rc) C (O) Ra, -N (Rc) S (O) 2Rd, - N (Rc) C (O) O (Ra), -N (Rc) S ( O) 2N (Rb) (Rc), -N (Rc) C (O) N (Rb) (Rc), - (CR1cR1d) q3-ORa, - (CR1cR1d) q3-OC (O) Ra, - (CR1cR1d ) q3-OC (O) N (Rb) (Rc), - (CR1cR1d) q3-S (O) Rd, - (CR1cR1d) q3-S (O) 2Rd, - (CR1cR1d) q3-S (O) 2N (Rb) (Rc), - (CR1cR1d) q3-C (O) Ra, - (CR1cR1d) q3-C (O) ORa, - (CR1cR1d) q3-C (O) N (Rb) (Rc), - (CR1cR1d) q3-N (Rb) (Rc), - (CR1cR1d) q3-N (Rc) C (O) Ra, - (CR1cR1d) q3-N (Rc) S (O) 2Rd, - (CR1cR1d) q3 -N (Rc) C (O) O (Ra), - (CR1cR1d) q3- N (Rc) S (O) 2N (Rb) (Rc), - (CR1cR1d) q3-N (Rc) C (O) N (Rb) (Rc), and - (CR1cR1d) q3-CN; Ra and Rc, at each occurrence, are each independently hydrogen, alkyl, haloalkyl, - (CR1aR1b) q3-A3, G1d, or - (CR1aR1b) q3-G1d; Rb, at each occurrence, is independently hydrogen, alkyl, haloalkyl, alkoxyalkyl, monocyclic cycloalkyl, - (CR1cR1d) q3- (monocyclic cycloalkyl), or haloalkoxyalkyl; Rd, at each occurrence, is independently alkyl, haloalkyl, - (CR1aR1b) q3-A3, G1d, or - (CR1aR1b) q3-G1d; G1d, at each occurrence, is independently a monocyclic heterocycle, a monocyclic heteroaryl, a phenyl group, a monocyclic cycloalkyl, or a monocyclic cycloalkenyl; each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of -N (Rb) 2, -CN, oxo, alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, and -OH ; each occurrence of A 3 is independently C (O) Rh, -S (O) 2Re, -C (O) N (Rh) 2, -C (S) N (Rb) 2, -S (O) 2N (Rh ) 2, - C (> = NORh) Rh, -N (Rh) C (O) Rh, -N (Rh) C (O) ORe, -N (Rh) S (O) 2Re, -N (Rh) C (O) N (Rh) 2, -N (Rh) S (O) 2N (Rh) 2, -CN, -ORh, or -N (Rh) 2; Re, at each occurrence, is independently C1-C4 alkyl, C1-C4 haloalkyl, monocyclic cycloalkyl, monocyclic heterocycle, or - (CR1cR1d) q3- (monocyclic cycloalkyl); Rf, at each occurrence, is independently hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, monocyclic heterocycle, monocyclic cycloalkyl, or - (CR2cR1d) q3- (monocyclic cycloalkyl); Rk is haloalkyl, - (CR1aR1b) q3-A3, G1d, or - (CR1aR1b) q3-G1d; Rk 'is hydrogen, alkyl, haloalkyl, - (CR1aR1b) q3-A3, G1d, or - (CR1aR1b) q3-G1d; R h, at each occurrence, is independently hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, monocyclic heterocycle, monocyclic cycloalkyl, or - (CR1cR1d) q3- (monocyclic cycloalkyl). |
| priorityDate | 2009-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 407.